Inventor · disambiguated record
Julia Leibold
Also filed as: LEIBOLD JULIA
32 granted patents·9 pending applications·325 citations·filing 2015–2024
98Inventor score
Top patents by PatentIndex Score
41 records- 0199US11826409B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 28, 2023·6 cites·20 claims
- 0299US11786584B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·4 cites·20 claims
- 0399US11324812B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 10, 2022·11 cites·20 claims
- 0499US11071773B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 27, 2021·8 cites·20 claims
- 0599US11065315B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 20, 2021·12 cites·20 claims
- 0699US11058754B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·14 cites·24 claims
- 0799US11027002B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 8, 2021·8 cites·20 claims
- 0899US10898560B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·11 cites·20 claims
- 0999US10898559B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·11 cites·20 claims
- 1099US10799569B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 13, 2020·14 cites·17 claims
- 1199US10526389B2Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 7, 2020·14 cites·20 claims
- 1298US10925948B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 23, 2021·12 cites·23 claims
- 1398US10577402B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Mar 3, 2020·12 cites·17 claims
- 1498US10550167B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 4, 2020·12 cites·17 claims
- 1598US10545154B2Method for the absolute quantification of naturally processed HLA-restricted cancer peptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Jan 28, 2020·17 cites·16 claims
- 1698US10532091B1Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 14, 2020·14 cites·20 claims
- 1798US10478480B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Nov 19, 2019·14 cites·20 claims
- 1898US10449238B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·18 cites·20 claims
- 1997US10662233B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 26, 2020·11 cites·20 claims
- 2097US10500259B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersimmatics biotechnology GmbH·Filed 2017·Granted Dec 10, 2019·17 cites·20 claims
- 2197US10383930B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 20, 2019·16 cites·16 claims
- 2297US10376568B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·14 cites·20 claims
- 2397US10238727B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Mar 26, 2019·13 cites·20 claims
- 2497US10155032B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Dec 18, 2018·12 cites·13 claims
- 2597US9993539B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jun 12, 2018·13 cites·13 claims
- 2696US9908920B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersimmatics biotechnology GmbH·Filed 2016·Granted Mar 6, 2018·15 cites·22 claims
- 2791US2024016908A1Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2889US11988669B2Method for the absolute quantification of naturally processed hla-restricted cancer peptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 21, 2024·2 cites·16 claims
- 2985US12180259B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 31, 2024·0 cites·19 claims
- 3085US12144852B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Nov 19, 2024·0 cites·19 claims
- 3185US12102670B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 1, 2024·0 cites·19 claims
- 3285US12097249B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 24, 2024·0 cites·20 claims
- 3385US12076381B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 3485US2024280583A1Method for the absolute quantification of naturally processed hla-restricted cancer peptidesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3585US2022152175A1Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3684US2022193212A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3784US2022211833A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3884US2022313805A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 3984US2022184193A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4084US2022184194A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
- 4181US2021275655A1Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julia Leibold files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →